Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 123 entries
Sorted by: Best Match Show Resources per page
Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B Patients.

Frontiers in immunology

Phillips S, Mistry S, Riva A, Cooksley H, Hadzhiolova-Lebeau T, Plavova S, Katzarov K, Simonova M, Zeuzem S, Woffendin C, Chen PJ, Peng CY, Chang TT, Lueth S, De Knegt R, Choi MS, Wedemeyer H, Dao M, Kim CW, Chu HC, Wind-Rotolo M, Williams R, Cooney E, Chokshi S.
PMID: 28611778
Front Immunol. 2017 May 29;8:621. doi: 10.3389/fimmu.2017.00621. eCollection 2017.

IFN-lambda (IFNλ) is a member of the type III IFN family and is reported to possess anti-pathogen, anti-cancer, and immunomodulatory properties; however, there are limited data regarding its impact on host immune responses CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov NCT01204762.

Cite
Phillips S, Mistry S, Riva A, et al. Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B Patients. Front Immunol. 2017;8:621doi: 10.3389/fimmu.2017.00621.
Phillips, S., Mistry, S., Riva, A., Cooksley, H., Hadzhiolova-Lebeau, T., Plavova, S., Katzarov, K., Simonova, M., Zeuzem, S., Woffendin, C., Chen, P. J., Peng, C. Y., Chang, T. T., Lueth, S., De Knegt, R., Choi, M. S., Wedemeyer, H., Dao, M., Kim, C. W., Chu, H. C., Wind-Rotolo, M., Williams, R., Cooney, E., & Chokshi, S. (2017). Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B Patients. Frontiers in immunology, 8621. https://doi.org/10.3389/fimmu.2017.00621
Phillips, Sandra, et al. "Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B Patients." Frontiers in immunology vol. 8 (2017): 621. doi: https://doi.org/10.3389/fimmu.2017.00621
Phillips S, Mistry S, Riva A, Cooksley H, Hadzhiolova-Lebeau T, Plavova S, Katzarov K, Simonova M, Zeuzem S, Woffendin C, Chen PJ, Peng CY, Chang TT, Lueth S, De Knegt R, Choi MS, Wedemeyer H, Dao M, Kim CW, Chu HC, Wind-Rotolo M, Williams R, Cooney E, Chokshi S. Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B Patients. Front Immunol. 2017 May 29;8:621. doi: 10.3389/fimmu.2017.00621. eCollection 2017. PMID: 28611778; PMCID: PMC5446997.
Copy Download .nbib Format: NLM
[Diagnostic imaging in liver cirrhosis].

Der Radiologe

Hammerstingl RM, Schwarz WV, Schmitt E, Faust D, Dietrich C, Zeuzem S, Vogl TJ.
PMID: 11715576
Radiologe. 2001 Oct;41(10):852-67. doi: 10.1007/s001170170056.

For the diagnosis of liver cirrhosis ultrasound, computed tomography, magnetic resonance imaging, and angiography are recommended as imaging modalities. Ultrasound of the liver is used as a screening imaging tool in cases of patients suspicious for diffuse liver disease...

Cite
Hammerstingl RM, Schwarz WV, Schmitt E, et al. Bildgebende Diagnostik der Leberzirrhose. [Diagnostic imaging in liver cirrhosis]. Radiologe. 2001;41(10):852-67doi: 10.1007/s001170170056.
Hammerstingl, R. M., Schwarz, W. V., Schmitt, E., Faust, D., Dietrich, C., Zeuzem, S., & Vogl, T. J. (2001). Bildgebende Diagnostik der Leberzirrhose. [Diagnostic imaging in liver cirrhosis]. Der Radiologe, 41(10), 852-67. https://doi.org/10.1007/s001170170056
Hammerstingl, R M, et al. "Bildgebende Diagnostik der Leberzirrhose." [Diagnostic imaging in liver cirrhosis]. Der Radiologe vol. 41,10 (2001): 852-67. doi: https://doi.org/10.1007/s001170170056
Hammerstingl RM, Schwarz WV, Schmitt E, Faust D, Dietrich C, Zeuzem S, Vogl TJ. Bildgebende Diagnostik der Leberzirrhose. [Diagnostic imaging in liver cirrhosis]. Radiologe. 2001 Oct;41(10):852-67. doi: 10.1007/s001170170056. German. PMID: 11715576.
Copy Download .nbib Format: NLM
[Is liver fibrosis a reversible event? Effect of pegylated interferon and ribavirin in patients with chronic hepatitis C].

Zeitschrift fur Gastroenterologie

Hofmann WP, Zeuzem S.
PMID: 16308928
Z Gastroenterol. 2003 Mar;41(3):271-4. doi: 10.1055/s-2003-37900.

No abstract available.

Cite
Hofmann WP, Zeuzem S. Ist Leberfibrose reversibel? Effekt von pegyliertem Interferon und Ribavirin bei Patienten mit chronischer Hepatitis C. [Is liver fibrosis a reversible event? Effect of pegylated interferon and ribavirin in patients with chronic hepatitis C]. Z Gastroenterol. 2003;41(3):271-4doi: 10.1055/s-2003-37900.
Hofmann, W. P., & Zeuzem, S. (2003). Ist Leberfibrose reversibel? Effekt von pegyliertem Interferon und Ribavirin bei Patienten mit chronischer Hepatitis C. [Is liver fibrosis a reversible event? Effect of pegylated interferon and ribavirin in patients with chronic hepatitis C]. Zeitschrift fur Gastroenterologie, 41(3), 271-4. https://doi.org/10.1055/s-2003-37900
Hofmann, W P, and Zeuzem, S. "Ist Leberfibrose reversibel? Effekt von pegyliertem Interferon und Ribavirin bei Patienten mit chronischer Hepatitis C." [Is liver fibrosis a reversible event? Effect of pegylated interferon and ribavirin in patients with chronic hepatitis C]. Zeitschrift fur Gastroenterologie vol. 41,3 (2003): 271-4. doi: https://doi.org/10.1055/s-2003-37900
Hofmann WP, Zeuzem S. Ist Leberfibrose reversibel? Effekt von pegyliertem Interferon und Ribavirin bei Patienten mit chronischer Hepatitis C. [Is liver fibrosis a reversible event? Effect of pegylated interferon and ribavirin in patients with chronic hepatitis C]. Z Gastroenterol. 2003 Mar;41(3):271-4. doi: 10.1055/s-2003-37900. German. PMID: 16308928.
Copy Download .nbib Format: NLM
Intraductal endoscopic radiofrequency ablation for the treatment of hilar non-resectable malignant bile duct obstruction.

World journal of gastrointestinal endoscopy

Tal AO, Vermehren J, Friedrich-Rust M, Bojunga J, Sarrazin C, Zeuzem S, Trojan J, Albert JG.
PMID: 24527176
World J Gastrointest Endosc. 2014 Jan 16;6(1):13-9. doi: 10.4253/wjge.v6.i1.13.

AIM: To evaluate the safety and technical success of endoscopic radiofrequency ablation (RFA) for palliative treatment of malignant hilar bile duct obstruction.METHODS: In this study, a recently CE and FDA-approved endoscopic RFA catheter was first tested in an ex...

Cite
Tal AO, Vermehren J, Friedrich-Rust M, et al. Intraductal endoscopic radiofrequency ablation for the treatment of hilar non-resectable malignant bile duct obstruction. World J Gastrointest Endosc. 2014;6(1):13-9doi: 10.4253/wjge.v6.i1.13.
Tal, A. O., Vermehren, J., Friedrich-Rust, M., Bojunga, J., Sarrazin, C., Zeuzem, S., Trojan, J., & Albert, J. G. (2014). Intraductal endoscopic radiofrequency ablation for the treatment of hilar non-resectable malignant bile duct obstruction. World journal of gastrointestinal endoscopy, 6(1), 13-9. https://doi.org/10.4253/wjge.v6.i1.13
Tal, Andrea Oliver, et al. "Intraductal endoscopic radiofrequency ablation for the treatment of hilar non-resectable malignant bile duct obstruction." World journal of gastrointestinal endoscopy vol. 6,1 (2014): 13-9. doi: https://doi.org/10.4253/wjge.v6.i1.13
Tal AO, Vermehren J, Friedrich-Rust M, Bojunga J, Sarrazin C, Zeuzem S, Trojan J, Albert JG. Intraductal endoscopic radiofrequency ablation for the treatment of hilar non-resectable malignant bile duct obstruction. World J Gastrointest Endosc. 2014 Jan 16;6(1):13-9. doi: 10.4253/wjge.v6.i1.13. PMID: 24527176; PMCID: PMC3921441.
Copy Download .nbib Format: NLM
Nernst effect in Tl-Ba-Ca-Cu-O high-Tc superconducting thin films.

Physical review. B, Condensed matter

Lengfellner H, Prettl W, Renk KF, Zeuner S.
PMID: 10009688
Phys Rev B Condens Matter. 1994 Apr 01;49(13):9080-9083. doi: 10.1103/physrevb.49.9080.

No abstract available.

Cite
Lengfellner H, Prettl W, Renk KF, et al. Nernst effect in Tl-Ba-Ca-Cu-O high-Tc superconducting thin films. Phys Rev B Condens Matter. 1994;49(13):9080-9083doi: 10.1103/physrevb.49.9080.
Lengfellner, H., Prettl, W., Renk, K. F., & Zeuner, S. (1994). Nernst effect in Tl-Ba-Ca-Cu-O high-Tc superconducting thin films. Physical review. B, Condensed matter, 49(13), 9080-9083. https://doi.org/10.1103/physrevb.49.9080
Lengfellner, et al. "Nernst effect in Tl-Ba-Ca-Cu-O high-Tc superconducting thin films." Physical review. B, Condensed matter vol. 49,13 (1994): 9080-9083. doi: https://doi.org/10.1103/physrevb.49.9080
Lengfellner H, Prettl W, Renk KF, Zeuner S. Nernst effect in Tl-Ba-Ca-Cu-O high-Tc superconducting thin films. Phys Rev B Condens Matter. 1994 Apr 01;49(13):9080-9083. doi: 10.1103/physrevb.49.9080. PMID: 10009688.
Copy Download .nbib Format: NLM
Early Viral Kinetics with Telbivudine, Tenofovir or Combination of Both in Immunotolerant Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B.

Infectious diseases and therapy

Leung NW, Herrmann E, Lau GK, Chan HL, So TM, Zeuzem S, Dong Y, Trylesinski A, Naoumov NV.
PMID: 25228496
Infect Dis Ther. 2014 Dec;3(2):191-202. doi: 10.1007/s40121-014-0039-5. Epub 2014 Sep 17.

INTRODUCTION: Viral kinetics has proved useful in understanding antiviral potency, determining antiviral profiles and optimizing treatment strategy.METHODS: This was a randomized, open-label study comparing the viral kinetics in 46 hepatitis B e antigen-positive patients during 12-week treatment with telbivudine...

Cite
Leung NW, Herrmann E, Lau GK, et al. Early Viral Kinetics with Telbivudine, Tenofovir or Combination of Both in Immunotolerant Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B. Infect Dis Ther. 2014;3(2):191-202doi: 10.1007/s40121-014-0039-5.
Leung, N. W., Herrmann, E., Lau, G. K., Chan, H. L., So, T. M., Zeuzem, S., Dong, Y., Trylesinski, A., & Naoumov, N. V. (2014). Early Viral Kinetics with Telbivudine, Tenofovir or Combination of Both in Immunotolerant Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B. Infectious diseases and therapy, 3(2), 191-202. https://doi.org/10.1007/s40121-014-0039-5
Leung, Nancy W Y, et al. "Early Viral Kinetics with Telbivudine, Tenofovir or Combination of Both in Immunotolerant Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B." Infectious diseases and therapy vol. 3,2 (2014): 191-202. doi: https://doi.org/10.1007/s40121-014-0039-5
Leung NW, Herrmann E, Lau GK, Chan HL, So TM, Zeuzem S, Dong Y, Trylesinski A, Naoumov NV. Early Viral Kinetics with Telbivudine, Tenofovir or Combination of Both in Immunotolerant Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B. Infect Dis Ther. 2014 Dec;3(2):191-202. doi: 10.1007/s40121-014-0039-5. Epub 2014 Sep 17. PMID: 25228496; PMCID: PMC4269624.
Copy Download .nbib Format: NLM
Application of Contrast-Enhanced Ultrasound to Detect Hepatic Hydrothorax in Patients with Liver Cirrhosis.

Ultraschall in der Medizin (Stuttgart, Germany : 1980)

Mücke VT, Fitting D, Dultz G, de Leuw P, Weiler N, Mücke MM, Hausmann J, Welsch C, Zeuzem S, Friedrich-Rust M, Bojunga J.
PMID: 32674185
Ultraschall Med. 2020 Jul 16; doi: 10.1055/a-1189-2937. Epub 2020 Jul 16.

PURPOSE:  Hepatic hydrothorax (HH) is defined as transudate in the pleural cavity in patients with decompensated liver cirrhosis (DC) without concomitant cardiopulmonary or pleural disease. It is associated with high short-term mortality. HH can evolve via translocation through diaphragmatic...

Cite
Mücke VT, Fitting D, Dultz G, et al. Die Anwendung von Kontrastmittelsonografie zur Detektion eines hepatischen Hydrothorax in Patienten mit Leberzirrhose. Application of Contrast-Enhanced Ultrasound to Detect Hepatic Hydrothorax in Patients with Liver Cirrhosis. Ultraschall Med. 2020;doi: 10.1055/a-1189-2937.
Mücke, V. T., Fitting, D., Dultz, G., de Leuw, P., Weiler, N., Mücke, M. M., Hausmann, J., Welsch, C., Zeuzem, S., Friedrich-Rust, M., & Bojunga, J. (2020). Die Anwendung von Kontrastmittelsonografie zur Detektion eines hepatischen Hydrothorax in Patienten mit Leberzirrhose. Application of Contrast-Enhanced Ultrasound to Detect Hepatic Hydrothorax in Patients with Liver Cirrhosis. Ultraschall in der Medizin (Stuttgart, Germany : 1980), . https://doi.org/10.1055/a-1189-2937
Mücke, Victoria Therese, et al. "Die Anwendung von Kontrastmittelsonografie zur Detektion eines hepatischen Hydrothorax in Patienten mit Leberzirrhose." Application of Contrast-Enhanced Ultrasound to Detect Hepatic Hydrothorax in Patients with Liver Cirrhosis. Ultraschall in der Medizin (Stuttgart, Germany : 1980) vol. (2020). doi: https://doi.org/10.1055/a-1189-2937
Mücke VT, Fitting D, Dultz G, de Leuw P, Weiler N, Mücke MM, Hausmann J, Welsch C, Zeuzem S, Friedrich-Rust M, Bojunga J. Die Anwendung von Kontrastmittelsonografie zur Detektion eines hepatischen Hydrothorax in Patienten mit Leberzirrhose. Application of Contrast-Enhanced Ultrasound to Detect Hepatic Hydrothorax in Patients with Liver Cirrhosis. Ultraschall Med. 2020 Jul 16; doi: 10.1055/a-1189-2937. Epub 2020 Jul 16. PMID: 32674185.
Copy Download .nbib Format: NLM
[No title available]

Zeitschrift fur Gastroenterologie

Zimmermann T, Jansen PL, Sarrazin C, Vollmar J, Zeuzem S.
PMID: 29986357
Z Gastroenterol. 2018 Jul;56(7):e53-e115. doi: 10.1055/a-0598-5242. Epub 2018 Jul 09.

No abstract available.

Cite
Zimmermann T, Jansen PL, Sarrazin C, et al. S3-Leitlinie „Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus (HCV) -Infektion“. . Z Gastroenterol. 2018;56(7):e53-e115doi: 10.1055/a-0598-5242.
Zimmermann, T., Jansen, P. L., Sarrazin, C., Vollmar, J., & Zeuzem, S. (2018). S3-Leitlinie „Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus (HCV) -Infektion“. . Zeitschrift fur Gastroenterologie, 56(7), e53-e115. https://doi.org/10.1055/a-0598-5242
Zimmermann, Tim, et al. "S3-Leitlinie „Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus (HCV) -Infektion“." . Zeitschrift fur Gastroenterologie vol. 56,7 (2018): e53-e115. doi: https://doi.org/10.1055/a-0598-5242
Zimmermann T, Jansen PL, Sarrazin C, Vollmar J, Zeuzem S. S3-Leitlinie „Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus (HCV) -Infektion“. . Z Gastroenterol. 2018 Jul;56(7):e53-e115. doi: 10.1055/a-0598-5242. Epub 2018 Jul 09. German. PMID: 29986357.
Copy Download .nbib Format: NLM
Weight Gain During Treatment of Bipolar Disorder (BD)-Facts and Therapeutic Options.

Frontiers in nutrition

Mangge H, Bengesser S, Dalkner N, Birner A, Fellendorf F, Platzer M, Queissner R, Pilz R, Maget A, Reininghaus B, Hamm C, Bauer K, Rieger A, Zelzer S, Fuchs D, Reininghaus E.
PMID: 31245376
Front Nutr. 2019 Jun 11;6:76. doi: 10.3389/fnut.2019.00076. eCollection 2019.

Bipolar disorder (BPD) is a mood disorder, which is characterized by alternating affective states, namely (hypo)mania, depression, and euthymia. Evidence is growing that BPD has indeed a biologic substrate characterized by chronic inflammation, oxidative stress, and disturbed energy metabolism....

Cite
Mangge H, Bengesser S, Dalkner N, et al. Weight Gain During Treatment of Bipolar Disorder (BD)-Facts and Therapeutic Options. Front Nutr. 2019;6:76doi: 10.3389/fnut.2019.00076.
Mangge, H., Bengesser, S., Dalkner, N., Birner, A., Fellendorf, F., Platzer, M., Queissner, R., Pilz, R., Maget, A., Reininghaus, B., Hamm, C., Bauer, K., Rieger, A., Zelzer, S., Fuchs, D., & Reininghaus, E. (2019). Weight Gain During Treatment of Bipolar Disorder (BD)-Facts and Therapeutic Options. Frontiers in nutrition, 676. https://doi.org/10.3389/fnut.2019.00076
Mangge, Harald, et al. "Weight Gain During Treatment of Bipolar Disorder (BD)-Facts and Therapeutic Options." Frontiers in nutrition vol. 6 (2019): 76. doi: https://doi.org/10.3389/fnut.2019.00076
Mangge H, Bengesser S, Dalkner N, Birner A, Fellendorf F, Platzer M, Queissner R, Pilz R, Maget A, Reininghaus B, Hamm C, Bauer K, Rieger A, Zelzer S, Fuchs D, Reininghaus E. Weight Gain During Treatment of Bipolar Disorder (BD)-Facts and Therapeutic Options. Front Nutr. 2019 Jun 11;6:76. doi: 10.3389/fnut.2019.00076. eCollection 2019. PMID: 31245376; PMCID: PMC6579840.
Copy Download .nbib Format: NLM
Epistatic interactions promote persistence of NS3-Q80K in HCV infection by compensating for protein folding instability.

The Journal of biological chemistry

Dultz G, Srikakulam SK, Konetschnik M, Shimakami T, Doncheva NT, Dietz J, Sarrazin C, Biondi RM, Zeuzem S, Tampé R, Kalinina OV, Welsch C.
PMID: 34339738
J Biol Chem. 2021 Sep;297(3):101031. doi: 10.1016/j.jbc.2021.101031. Epub 2021 Jul 31.

The Q80K polymorphism in the NS3-4A protease of the hepatitis C virus is associated with treatment failure of direct-acting antiviral agents. This polymorphism is highly prevalent in genotype 1a infections and stably transmitted between hosts. Here, we investigated the...

Cite
Dultz G, Srikakulam SK, Konetschnik M, et al. Epistatic interactions promote persistence of NS3-Q80K in HCV infection by compensating for protein folding instability. J Biol Chem. 2021;297(3):101031doi: 10.1016/j.jbc.2021.101031.
Dultz, G., Srikakulam, S. K., Konetschnik, M., Shimakami, T., Doncheva, N. T., Dietz, J., Sarrazin, C., Biondi, R. M., Zeuzem, S., Tampé, R., Kalinina, O. V., & Welsch, C. (2021). Epistatic interactions promote persistence of NS3-Q80K in HCV infection by compensating for protein folding instability. The Journal of biological chemistry, 297(3), 101031. https://doi.org/10.1016/j.jbc.2021.101031
Dultz, Georg, et al. "Epistatic interactions promote persistence of NS3-Q80K in HCV infection by compensating for protein folding instability." The Journal of biological chemistry vol. 297,3 (2021): 101031. doi: https://doi.org/10.1016/j.jbc.2021.101031
Dultz G, Srikakulam SK, Konetschnik M, Shimakami T, Doncheva NT, Dietz J, Sarrazin C, Biondi RM, Zeuzem S, Tampé R, Kalinina OV, Welsch C. Epistatic interactions promote persistence of NS3-Q80K in HCV infection by compensating for protein folding instability. J Biol Chem. 2021 Sep;297(3):101031. doi: 10.1016/j.jbc.2021.101031. Epub 2021 Jul 31. PMID: 34339738; PMCID: PMC8405986.
Copy Download .nbib Format: NLM
Trends and the course of liver cirrhosis and its complications in Germany: Nationwide population-based study (2005 to 2018).

The Lancet regional health. Europe

Gu W, Hortlik H, Erasmus HP, Schaaf L, Zeleke Y, Uschner FE, Ferstl P, Schulz M, Peiffer KH, Queck A, Sauerbruch T, Brol MJ, Rohde G, Sanchez C, Moreau R, Arroyo V, Zeuzem S, Welsch C, Trebicka J.
PMID: 34901909
Lancet Reg Health Eur. 2021 Nov 04;12:100240. doi: 10.1016/j.lanepe.2021.100240. eCollection 2022 Jan.

BACKGROUND: Cirrhosis is known to have a high prevalence and mortality worldwide. However, in Europe, the epidemiology of cirrhosis is possibly undergoing demographic changes, and etiologies may have changed due to improvements in standard of care. The aim of...

Cite
Gu W, Hortlik H, Erasmus HP, et al. Trends and the course of liver cirrhosis and its complications in Germany: Nationwide population-based study (2005 to 2018). Lancet Reg Health Eur. 2021;12:100240doi: 10.1016/j.lanepe.2021.100240.
Gu, W., Hortlik, H., Erasmus, H. P., Schaaf, L., Zeleke, Y., Uschner, F. E., Ferstl, P., Schulz, M., Peiffer, K. H., Queck, A., Sauerbruch, T., Brol, M. J., Rohde, G., Sanchez, C., Moreau, R., Arroyo, V., Zeuzem, S., Welsch, C., & Trebicka, J. (2022). Trends and the course of liver cirrhosis and its complications in Germany: Nationwide population-based study (2005 to 2018). The Lancet regional health. Europe, 12100240. https://doi.org/10.1016/j.lanepe.2021.100240
Gu, Wenyi, et al. "Trends and the course of liver cirrhosis and its complications in Germany: Nationwide population-based study (2005 to 2018)." The Lancet regional health. Europe vol. 12 (2022): 100240. doi: https://doi.org/10.1016/j.lanepe.2021.100240
Gu W, Hortlik H, Erasmus HP, Schaaf L, Zeleke Y, Uschner FE, Ferstl P, Schulz M, Peiffer KH, Queck A, Sauerbruch T, Brol MJ, Rohde G, Sanchez C, Moreau R, Arroyo V, Zeuzem S, Welsch C, Trebicka J. Trends and the course of liver cirrhosis and its complications in Germany: Nationwide population-based study (2005 to 2018). Lancet Reg Health Eur. 2021 Nov 04;12:100240. doi: 10.1016/j.lanepe.2021.100240. eCollection 2022 Jan. PMID: 34901909; PMCID: PMC8640738.
Copy Download .nbib Format: NLM
Reproducibility and limitations of transient elastography.

Liver international : official journal of the International Association for the Study of the Liver

Friedrich-Rust M, Zeuzem S.
PMID: 19413664
Liver Int. 2009 May;29(5):619-20. doi: 10.1111/j.1478-3231.2009.02032.x.

No abstract available.

Cite
Friedrich-Rust M, Zeuzem S. Reproducibility and limitations of transient elastography. Liver Int. 2009;29(5):619-20doi: 10.1111/j.1478-3231.2009.02032.x.
Friedrich-Rust, M., & Zeuzem, S. (2009). Reproducibility and limitations of transient elastography. Liver international : official journal of the International Association for the Study of the Liver, 29(5), 619-20. https://doi.org/10.1111/j.1478-3231.2009.02032.x
Friedrich-Rust, Mireen, and Zeuzem, Stefan. "Reproducibility and limitations of transient elastography." Liver international : official journal of the International Association for the Study of the Liver vol. 29,5 (2009): 619-20. doi: https://doi.org/10.1111/j.1478-3231.2009.02032.x
Friedrich-Rust M, Zeuzem S. Reproducibility and limitations of transient elastography. Liver Int. 2009 May;29(5):619-20. doi: 10.1111/j.1478-3231.2009.02032.x. PMID: 19413664.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 123 entries